PROTEOMICS SHARED RESOURCE The Proteomics SR (PROT) is a state-of-the-art facility that brings cutting edge proteomics research to LCCC faculty. It is a well-established shared resource (SR) that provides consultation for the design of experiments, sample preparation, mass spectrometry (MS) and extensive data analysis for LCCC members. Directed by an expert staff, the SR is full service allowing users with projects but little experience to understand the range of data acquisition opportunities. The SR also has the instrumentation that allows more experienced users access to expensive, well maintained mass spectrometers. Core staff and expert users have extended the capabilities with innovative techniques such as the MIB/MS analysis of cell wide kinase activity. Contributions include validating and characterizing cancer-relevant drug targets, quantifying proteome and signaling network changes in response to emerging therapeutics, studying the dynamic regulation of the kinome, describing how specific pathways globally remodel cancer proteomes independent of changes in gene expression, and determining how protein interaction networks are dysregulated in cancer. Instrumentation includes; state-of-the-art mass spectrometers include: Thermo Lumos, Thermo QExactive HF- X, Thermo QExactive Biopharma, Thermo QExactive HF, Thermo Orbitrap Velos and Sciex 5800 MALDI/TOF/TOF. All were partially purchased or leased by LCCC including four within the last four years. The purchase and maintenance of the current PROT SR instruments are beyond the means of any individual lab. LCCC investments have made it possible for multiple labs to access high end technology. The cost of PROT SR services are generally lower by 25% than comparable private company or other academic institutions and LCCC members receive an additional discount making the facility quite cost effective. The LCCC is requesting $135,301 from the CCSG, which represents 21% of the total operating budget; 48% of the SR usage is by LCCC faculty.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Chapel Hill
United States
Zip Code
Ma, Shaohua; Paiboonrungruan, Chorlada; Yan, Tiansheng et al. (2018) Targeted therapy of esophageal squamous cell carcinoma: the NRF2 signaling pathway as target. Ann N Y Acad Sci 1434:164-172
Aung, Kyaw L; Fischer, Sandra E; Denroche, Robert E et al. (2018) Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Clin Cancer Res 24:1344-1354
Suh, Junghyun L; Watts, Brian; Stuckey, Jacob I et al. (2018) Quantitative Characterization of Bivalent Probes for a Dual Bromodomain Protein, Transcription Initiation Factor TFIID Subunit 1. Biochemistry 57:2140-2149
Brock, William J; Beaudoin, James J; Slizgi, Jason R et al. (2018) Bile Acids as Potential Biomarkers to Assess Liver Impairment in Polycystic Kidney Disease. Int J Toxicol 37:144-154
Thomas, Nancy E; Edmiston, Sharon N; Tsai, Yihsuan S et al. (2018) Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis. Am J Dermatopathol :
Bensen, Jeannette T; Graff, Mariaelisa; Young, Kristin L et al. (2018) A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women. Breast Cancer Res 20:45
Hall, Marissa G; Marteau, Theresa M; Sunstein, Cass R et al. (2018) Public support for pictorial warnings on cigarette packs: an experimental study of US smokers. J Behav Med 41:398-405
Thorsson, V├ęsteinn; Gibbs, David L; Brown, Scott D et al. (2018) The Immune Landscape of Cancer. Immunity 48:812-830.e14
Wu, Bing; Zhang, Song; Guo, Zengli et al. (2018) RAS P21 Protein Activator 3 (RASA3) Specifically Promotes Pathogenic T Helper 17 Cell Generation by Repressing T-Helper-2-Cell-Biased Programs. Immunity 49:886-898.e5
Ding, Li; Bailey, Matthew H; Porta-Pardo, Eduard et al. (2018) Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell 173:305-320.e10

Showing the most recent 10 out of 1525 publications